Minimal change nephrotic syndrome due to certolizumab pegol, an anti-tumor necrosis factor-alpha monoclonal antibody for treatment of rheumatoid arthritis

Detalles Bibliográficos
Autores principales: Sugiyama, Masafumi, Okuda, Saki, Hirooka, Yasuaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Letter to the Editor (Case report)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8892364/
https://www.ncbi.nlm.nih.gov/pubmed/35252744
http://dx.doi.org/10.1093/rap/rkac012

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8892364/
https://www.ncbi.nlm.nih.gov/pubmed/35252744
http://dx.doi.org/10.1093/rap/rkac012

Ejemplares similares